Clinical and Molecular Hepatology

"Kyu Sung Rim"

Original Articles

Viral hepatitis

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B: Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kwang-il Kim, Soo-Hwan Kim, Kyu Sung Rim, Seong Gyu Hwang; Clin Mol Hepatol 2019;25(1):52-64.
Published online October 23, 2018; DOI: https://doi.org/10.3350/cmh.2018.0040

Abstract
PDF

Background/Aims
Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic steatosis on the risk for hepatocellular carcinoma (HCC) in CHB patients without excessive alcohol intake.
Methods
Consecutive CHB patients who underwent liver biopsy from January 2007 to December 2015 were included. The association between hepatic steatosis (≥ 5%) and subsequent HCC risk was analyzed. Inverse probability weighting (IPW) using the propensity score was applied to adjust for differences in patient characteristics, including metabolic factors.
Results
Fatty liver was histologically proven in 70 patients (21.8%) among a total of 321 patients. During the median (interquartile range) follow-up of 5.3 (2.9–8.3) years, 17 of 321 patients (5.3%) developed HCC: 8 of 70 patients (11.4%) with fatty liver and 9 of 251 patients (3.6%) without fatty liver. The five-year cumulative incidences of HCC among patients without and with fatty liver were 1.9% and 8.2%, respectively (P=0.004). Coexisting fatty liver was associated with a higher risk for HCC (adjusted hazards ratio [HR], 3.005; 95% confidence interval [CI], 1.122–8.051; P=0.03). After balancing with IPW, HCC incidences were not significantly different between the groups (P=0.19), and the association between fatty liver and HCC was not significant (adjusted HR, 1.709; 95% CI, 0.404–7.228; P=0.47).
Conclusions
Superimposed NAFLD was associated with a higher HCC risk in CHB patients. However, the association between steatosis per se and HCC risk was not evident after adjustment for metabolic factors.

Citations

Citations to this article as recorded by

High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs
Emi Sometani, Hayato Hikita, Kazuhiro Murai, Hidenori Toyoda, Satoshi Tanaka, Tsugiko Oze, Jihyun Sung, Akiyoshi Shimoda, Makoto Fukuoka, Satoshi Shigeno, Keisuke Fukutomi, Kumiko Shirai, Yuki Tahata, Yoshinobu Saito, Akira Nishio, Kunimaro Furuta, Takahi
Hepatology Research.2025; 55(1): 22. CrossRef
Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B
Xinrong Zhang, Vy H Nguyen, Leslie Yeeman Kam, Scott D Barnett, Linda Henry, Ramsey Cheung, Mindie H Nguyen
The Journal of Infectious Diseases.2025; 231(4): 1079. CrossRef
Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B
Navavee Uman, Apichat Kaewdech, Pimsiri Sripongpun, Naichaya Chamroonkul, Teerha Piratvisuth
Gastroenterology Report.2025;[Epub] CrossRef
Association of concomitant MASLD and hepatitis B virus with clinical prognosis in hepatocellular carcinoma after curative resection
Chih-Jan Ko
American Journal of Cancer Research.2025; 15(2): 737. CrossRef
Study on Ultrasound-Assisted Diagnosis of CHB Complicated with NAFLD Hepatic Fibrosis Based on Deep Learning
Xiuling Huang, Shan Huang, Changfeng Dong, Nuo Chen, Yuxuan Wang, Changmiao Wang, Yongquan Zhang, Cheng Feng
Journal of Imaging Informatics in Medicine.2025; 38(6): 4349. CrossRef
The outcomes and mechanisms of chronic hepatitis B complicated by metabolic dysfunction-associated steatotic liver disease
Mao-Ping Li, Kai-Zhong Luo
Hepatobiliary & Pancreatic Diseases International.2025; 24(5): 476. CrossRef
Impact of Metabolic Dysfunction-Associated Fatty Liver Disease of Varying Severity on Antiviral Treatment Outcomes and Clinical Prognosis in Patients with Chronic Hepatitis B: A Systematic Review and Meta-analysis
Qianqian Zhu, Chengde Su, Mingdan Li, Yali Xu, Qian Liu, Ying Zhang, Xinyi Zhang, Qiuxiang Li, Huajun Wang, Yawen Luo, Ping Yang
Infectious Diseases and Therapy.2025; 14(8): 1599. CrossRef
Chronic hepatitis B: Is it time for expanded antiviral treatment?
Manish Manrai, Atul A Jha, Aditya V Pachisia, Saurabh Dawra
World Journal of Virology.2025;[Epub] CrossRef
Hepatocellular carcinoma risk stratification to identify patients suitable for intensive surveillance in viral hepatitis: the SELECT score
Yeun-Yoon Kim, Won Chang, Jeong Min Lee, Se Woo Kim, Jae Seok Bae, Jeongin Yoo, Sun Kyung Jeon, HeeSoo Kim, Young Hoon Kim, Jin-Young Choi, Eun Ju Cho, Yun Bin Lee, Sook-Hyang Jeong, Do Young Kim, Yunhee Choi, Jeong Hee Yoon
European Radiology.2025;[Epub] CrossRef
Influence of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with HBV-related acute-on-chronic liver failure
Rui-Min Lai, Li-Xi Yao, Shan Lin, Jia-Hui Zhou, Bing-Ping Liu, Zhao-Yi Liang, Tianbin Chen, Jia-Ji Jiang, Qi Zheng, Yueyong Zhu
Expert Review of Gastroenterology & Hepatology.2024; 18(1-3): 103. CrossRef
Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patients
Yu-Tong Sun, Qian-Qian Chen
World Journal of Hepatology.2024; 16(1): 109. CrossRef
Effect of metabolic dysfunction‑associated fatty liver disease on the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta‑analysis
Sixing Shen, Lingyan Pan
Experimental and Therapeutic Medicine.2024;[Epub] CrossRef
Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B
Danny Con, Steven Tu, Daniel Clayton-Chubb, John S. Lubel, Amanda J. Nicoll, Rohit Sawhney, Stephen Bloom
Digestive Diseases and Sciences.2024; 69(4): 1496. CrossRef
Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis
Shi-Yi Liu, Dian Wang, Jing Liu, Lu-Ping Yang, Gong-Ying Chen
World Journal of Hepatology.2024; 16(3): 465. CrossRef
Navigating the Nomenclature of Liver Steatosis: Transitioning from NAFLD to MAFLD and MASLD - Understanding Affinities and Differences
Apichat Kaewdech, Pimsiri Sripongpun
Siriraj Medical Journal.2024; 76(4): 234. CrossRef
Nonalcoholic fatty liver disease in Sub-Saharan Africa: A descriptive study of the range of histopathological findings in the South-West zone of Nigeria
Olusegun Sylvester Ojo, Olusegun Adekanle, Dennis Ndububa, Olawunmi Kolawole, Omolade Adefolabi Betiku
Nigerian Journal of Gastroenterology and Hepatology.2024; 16(1): 42. CrossRef
Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation
Jun Wang, Hongzhou Lu, Qian Li
Frontiers in Immunology.2024;[Epub] CrossRef
Prevalence of nonalcoholic fatty liver disease in patients with hepatitis B: A meta-analysis
Li Zhang, Hong-Di Wu, Yuan-Fang Qian, Hong-Yan Xu
World Journal of Clinical Cases.2024; 12(25): 5749. CrossRef
Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma
Gupse Adali, Huseyin Aykut, Nermin Mutlu Bilgic, Yusuf Yilmaz
Heliyon.2024; 10(18): e37990. CrossRef
Revolutionizing the understanding of liver disease: Metabolism, function and future
Arnulfo E Morales-Galicia, Mariana M Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Nahum Méndez-Sánchez
World Journal of Hepatology.2024; 16(12): 1365. CrossRef
Hepatic steatosis: Ultrasound assessment using attenuation imaging (ATI) with liver biopsy correlation
Christopher J Welman, Jacqualine Saunders, Marilyn Zelesco, Steven Abbott, Glenn Boardman, Oyekoya T Ayonrinde
Journal of Medical Imaging and Radiation Oncology.2023; 67(1): 45. CrossRef
Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection
Chang-Hai Liu, Wei Jiang, Dong-Bo Wu, Qing-Min Zeng, You-Juan Wang, Hong Tang
Digestive Diseases and Sciences.2023; 68(4): 1605. CrossRef
The interplay of long noncoding RNAs and hepatitis B virus
Nima Sarfaraz, Srinivas Somarowthu, Michael J. Bouchard
Journal of Medical Virology.2023;[Epub] CrossRef
Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysis
Xianhua Mao, Ka Shing Cheung, Chengzhi Peng, Lung‐Yi Mak, Ho Ming Cheng, James Fung, Noam Peleg, Howard H.‐W. Leung, Rajneesh Kumar, Jeong‐Hoon Lee, Amir Shlomai, Man‐Fung Yuen, Wai‐Kay Seto
Hepatology.2023; 77(5): 1735. CrossRef
Letter: metabolic dysfunction‐associated fatty liver disease increases risk of all‐cause mortality in patients with chronic hepatitis C
Qianwen Zhao, Yunlei Deng
Alimentary Pharmacology & Therapeutics.2023; 57(2): 272. CrossRef
The association of fatty liver and risk of hepatocellular carcinoma in HBV or HCV infected individuals: a systematic review and meta-analysis
Cheng-Long Han, Bao-Wen Tian, Chun-Cheng Yang, Ya-Fei Yang, Yun-Long Ma, Zi-Niu Ding, Lun-Jie Yan, Hui Liu, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Dong-Xu Wang, Tao Li
Expert Review of Gastroenterology & Hepatology.2023; 17(2): 189. CrossRef
Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis
Lili Liu, Hong Li, Yang Zhang, Jing Zhang, Zhenhuan Cao
Heliyon.2023; 9(1): e13113. CrossRef
Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection
Haifeng Lv, Yanming Jiang, Geli Zhu, Shiyi Liu, Dian Wang, Jie Wang, Ke Zhao, Jing Liu
Scientific Reports.2023;[Epub] CrossRef
Positive hepatitis B core antibody is associated with advanced fibrosis and mortality in nonalcoholic fatty liver disease
Pengyan Zhang, Zhenqiu Liu, Hong Fan, Tingting Shi, Xinyu Han, Chen Suo, Xingdong Chen, Tiejun Zhang
European Journal of Gastroenterology & Hepatology.2023; 35(3): 294. CrossRef
A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD
Jian Wang, Rui Huang, Jiacheng Liu, Ruimin Lai, Yilin Liu, Chuanwu Zhu, Yuanwang Qiu, Zebao He, Shengxia Yin, Yuxin Chen, Xiaomin Yan, Weimao Ding, Qi Zheng, Jie Li, Chao Wu
Journal of Viral Hepatitis.2023; 30(4): 287. CrossRef
Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease
You-Wen Tan, Jia-Min Wang, Xing-Bei Zhou
World Journal of Hepatology.2023; 15(2): 237. CrossRef
Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma
Ke-Gong Xiong, Tai-Shun Lin, Jin-Feng Kong, Qing-Biao Lin, Li-Fang Chen, Kun-Yu Ke
Medicine.2023; 102(9): e33062. CrossRef
Pyroptosis, Metabolism, and Oxidation in Tumorigenesis: Mechanisms and Therapeutic Implications
Qi Cao, Jia-Bao Zhang, Di-Yang Sun, Jiang-Tao Fu, Wen-Bin Wu, Xiao-Fei Chen, Dong-Jie Li, Pei Wang
Antioxidants & Redox Signaling.2023; 39(7-9): 512. CrossRef
The hepatitis B virus promotes the progression of non-alcoholic fatty liver disease through incomplete autophagy
Yang Wang, Jiaxi Li, Shanshan Wang, Yuheng Pang, Pengxiang Liu, Bangxiang Xie, Shuangshuang Dou, Tongwang Yang, Xiaoni Liu, Ying Shi, Dexi Chen
Free Radical Biology and Medicine.2023; 204: 326. CrossRef
Impact of prior HBV, HAV, and HEV infection on non‐alcoholic fatty liver disease
Stephanos Vassilopoulos, Markos Kalligeros, Athanasios Vassilopoulos, Fadi Shehadeh, Gregorio Benitez, Matthew Kaczynski, Ingrid Lazaridou, Kittichai Promrat, Jack R. Wands, Eleftherios Mylonakis
Journal of Viral Hepatitis.2023; 30(8): 685. CrossRef
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik
JHEP Reports.2023; 5(9): 100810. CrossRef
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vince
Clinical and Molecular Hepatology.2023; 29(3): 705. CrossRef
The Global Prevalence of Nonalcoholic Fatty Liver Disease and its Association With Cancers: Systematic Review and Meta-Analysis
Nor Asiah Muhamad, Nur Hasnah Maamor, Fatin Norhasny Leman, Zuraifah Asrah Mohamad, Sophia Karen Bakon, Mohd Hatta Abdul Mutalip, Izzah Athirah Rosli, Tahir Aris, Nai Ming Lai, Muhammad Radzi Abu Hassan
Interactive Journal of Medical Research.2023; 12: e40653. CrossRef
Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients
Rui-Min Lai, Shan Lin, Miao-Miao Wang, Na Li, Jia-Hui Zhou, Xiao-Yu Lin, Tian-Bin Chen, Yue-Yong Zhu, Qi Zheng
World Journal of Hepatology.2023; 15(8): 964. CrossRef
Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV–HIV Co-infected Adults
Richard K. Sterling, Wendy C. King, Mandana Khalili, David E. Kleiner, Amanda S. Hinerman, Mark Sulkowski, Raymond T. Chung, Mamta K. Jain, M auricio Lisker-Melman, David K. Wong, Marc G. Ghany
Digestive Diseases and Sciences.2022; 67(2): 676. CrossRef
Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia
Madhumita Premkumar, Yogesh K. Chawla
Journal of Clinical and Experimental Hepatology.2022; 12(1): 144. CrossRef
Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection
Si Ho Kim, Eun Ju Cho, Boo‐ok Jang, Kyunghan Lee, Jae Kyun Choi, Gwang Hyeon Choi, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Yun Bin Lee, Jeong‐Hwan Yoon, Jin‐Wook Kim, Sook‐Hyang Jeong, Eun Sun Jang
Liver International.2022; 42(2): 320. CrossRef
Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver
Mi Na Kim, Kyungdo Han, Juhwan Yoo, Seong Gyu Hwang, Sang Hoon Ahn
Alimentary Pharmacology & Therapeutics.2022; 55(1): 97. CrossRef
Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC
Lei Liu, Si Xie, Yu-Xian Teng, Zhu-Jian Deng, Kang Chen, Hao-Tian Liu, Rong-Rui Huo, Xiu-Mei Liang, Ping-Ping Guo, Da-Long Yang, Liang Ma, Bang-De Xiang, Le-Qun Li, Jian-Hong Zhong
Frontiers in Oncology.2022;[Epub] CrossRef
Severe Hepatic Steatosis Is Associated With Low-Level Viremia and Advanced Fibrosis in Patients With Chronic Hepatitis B in North America
Hin Hin Ko, Nishi H. Patel, Sarah Haylock-Jacobs, Karen Doucette, Mang M. Ma, Curtis Cooper, Erin Kelly, Magdy Elkhashab, Edward Tam, Robert Bailey, Alexander Wong, Gerald Minuk, Philip Wong, Scott K. Fung, Giada Sebastiani, Alnoor Ramji, Carla S. Coffin
Gastro Hep Advances.2022; 1(1): 106. CrossRef
MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients
Xiaoman Chen, Jing Zhou, Lili Wu, Xiang Zhu, Hong Deng
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 673. CrossRef
Validation for models for tumor recurrence after liver transplantation in hepatectomy patients
Sung Joon Kim, Jong Man Kim, Nam-Joon Yi, Gyu-Seong Choi, Kwang-Woong Lee, Kyung-Suk Suh, Jae-Won Joh
Annals of Surgical Treatment and Research.2022; 102(3): 131. CrossRef
A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease
Xuemei Tao, Lin Chen, Youfei Zhao, Yonggang Liu, Ruifang Shi, Bei Jiang, Yuqiang Mi, Liang Xu
Frontiers in Medicine.2022;[Epub] CrossRef
Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients
Han Ah Lee, Hyun Woong Lee, Younhee Park, Hyon-Suk Kim, Yeon Seok Seo
Journal of Clinical Medicine.2022; 11(6): 1729. CrossRef
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
Clinical and Molecular Hepatology.2022; 28(2): 150. CrossRef
Precision medicine in the era of potent antiviral therapy for chronic hepatitis B
Eileen L. Yoon, Dae Won Jun
Journal of Gastroenterology and Hepatology.2022; 37(7): 1191. CrossRef
Metabolic Risk Factors Are Associated with the Disease Severity and Prognosis of Hepatitis B Virus-Related Acute on Chronic Liver Failure
Lu Chen, Jinjin Dai, Qing Xie, Xiaolin Wang, Wei Cai
Gut and Liver.2022; 16(3): 456. CrossRef
Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia
Ming Yang, Lai Wei
Liver International.2022; 42(9): 1981. CrossRef
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
Clinical and Molecular Hepatology.2022; 28(3): 425. CrossRef
Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease
Han Ah Lee, Seung-seob Kim, Jin-Young Choi, Yeon Seok Seo, Beom Jin Park, Ki Choon Sim, Seung Up Kim
Abdominal Radiology.2022; 47(11): 3733. CrossRef
Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease
Xin Tong, Yu Song, Shengxia Yin, Jian Wang, Rui Huang, Chao Wu, Junping Shi, Jie Li
Chinese Medical Journal.2022; 135(14): 1653. CrossRef
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen
Clinical and Molecular Hepatology.2022; 28(4): 790. CrossRef
Progress in understanding of association between metabolic associated fatty liver disease and viral infectious diseases
Zhao-Chun Chi
World Chinese Journal of Digestology.2022; 30(18): 783. CrossRef
Interaction and Possible Mechanism between Non-Alcoholic Fatty Liver Disease and Chronic Hepatitis B
博诗陈
Advances in Clinical Medicine.2022; 12(11): 10453. CrossRef
Radiomics Analysis of Magnetic Resonance Proton Density Fat Fraction for the Diagnosis of Hepatic Steatosis in Patients With Suspected Non-Alcoholic Fatty Liver Disease
Ki Choon Sim, Min Ju Kim, Yongwon Cho, Hyun Jin Kim, Beom Jin Park, Deuk Jae Sung, Na Yeon Han, Yeo Eun Han, Tae Hyung Kim, Yoo Jin Lee
Journal of Korean Medical Science.2022;[Epub] CrossRef
Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease
Changtian Su, Qin Yang
Frontiers in Pharmacology.2022;[Epub] CrossRef
NAFLD and HBV interplay - related mechanisms underlying liver disease progression
Evanthia Tourkochristou, Stelios F. Assimakopoulos, Konstantinos Thomopoulos, Markos Marangos, Christos Triantos
Frontiers in Immunology.2022;[Epub] CrossRef
Metabolic syndromes, hepatitis B virus (HBV), and hepatitis C virus as three factors involved in the development of hepatic steatosis: a systematic review and meta-analysis
Masoud Keikha, Amirhossein Sahebkar, Tannaz Jamialahmadi, Mohsen Karbalaei
Reviews and Research in Medical Microbiology.2022; 33(3): 139. CrossRef
Secondary prevention of hepatitis B virus‐related hepatocellular carcinoma with current antiviral therapies
Jonggi Choi, Young‐Suk Lim
The Kaohsiung Journal of Medical Sciences.2021; 37(4): 262. CrossRef
HRD1 attenuates the high uptake of [18F]FDG in hepatocellular carcinoma PET imaging
Ai-Mei Li, Xia-Wen Lin, Jing-Tao Shen, Min Li, Qi-Huang Zheng, Zheng-Yang Zhou, Ming Shi
Nuclear Medicine and Biology.2021; 96-97: 27. CrossRef
The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
Minah Kim, Yeonju Lee, Jun Sik Yoon, Minjong Lee, So Shin Kye, Sun Woong Kim, Yuri Cho
Cancers.2021; 13(10): 2301. CrossRef
Association of Metabolic Risk Factors With Risks of Cancer and All‐Cause Mortality in Patients With Chronic Hepatitis B
Yun Bin Lee, Hyemi Moon, Jeong‐Hoon Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Fabien Zoulim, Juneyoung Lee, Jung‐Hwan Yoon
Hepatology.2021; 73(6): 2266. CrossRef
Pyroptosis: mechanisms and diseases
Pian Yu, Xu Zhang, Nian Liu, Ling Tang, Cong Peng, Xiang Chen
Signal Transduction and Targeted Therapy.2021;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B
Laurens A. van Kleef, Hannah S.J. Choi, Willem P. Brouwer, Bettina E. Hansen, Keyur Patel, Robert A. de Man, Harry L.A. Janssen, Robert J. de Knegt, Milan J. Sonneveld
JHEP Reports.2021; 3(5): 100350. CrossRef
Systematic review with meta‐analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B
Qi Zheng, Biyao Zou, Yuankai Wu, Yeehui Yeo, Huizhen Wu, Christopher D Stave, Ramsey C. Cheung, Mindie H. Nguyen
Alimentary Pharmacology & Therapeutics.2021; 54(9): 1100. CrossRef
Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy
Rong Fan, Junqi Niu, Hong Ma, Qing Xie, Jun Cheng, Huiying Rao, Xiaoguang Dou, Jianping Xie, Wei Zhao, Jie Peng, Zhiliang Gao, Hongbo Gao, Xinyue Chen, Jinjun Chen, Qiang Li, Hong Tang, Zhengang Zhang, Hong Ren, Mingliang Cheng, Xieer Liang, Chaonan Zhu,
Alimentary Pharmacology & Therapeutics.2021; 54(3): 329. CrossRef
Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy
Joo Hyun Oh, Hye Won Lee, Dong Hyun Sinn, Jun Yong Park, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Wonseok Kang, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Yong-Han Paik
Hepatology International.2021; 15(4): 892. CrossRef
Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion
Yi-Wen Shi, Rui-Xu Yang, Jian-Gao Fan
World Journal of Gastroenterology.2021; 27(26): 3971. CrossRef
The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Journal of Hepatocellular Carcinoma.2021; Volume 8: 467. CrossRef
REPLY:
Yun Bin Lee, Juneyoung Lee
Hepatology.2021; 74(2): 1135. CrossRef
Reply
Hye Won Lee, Beom Kyung Kim
Clinical Gastroenterology and Hepatology.2020; 18(1): 264. CrossRef
Magnetic resonance imaging of obesity and metabolic disorders: Summary from the 2019 ISMRM Workshop
Houchun H. Hu, Rosa Tamara Branca, Diego Hernando, Dimitrios C. Karampinos, Jürgen Machann, Charles A. McKenzie, Holden H. Wu, Takeshi Yokoo, S. Sendhil Velan
Magnetic Resonance in Medicine.2020; 83(5): 1565. CrossRef
Abnormal CD44 activation of hepatocytes with nonalcoholic fatty accumulation in rat hepatocarcinogenesis
Miao Fang, Min Yao, Jie Yang, Wen-Jie Zheng, Li Wang, Deng-Fu Yao
World Journal of Gastrointestinal Oncology.2020; 12(1): 66. CrossRef
Chronic hepatitis B and non‐alcoholic fatty liver disease: Conspirators or competitors?
Jianbin Zhang, Shuangzhe Lin, Daixi Jiang, Mengting Li, Yuanwen Chen, Jun Li, Jiangao Fan
Liver International.2020; 40(3): 496. CrossRef
Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B
Jonggi Choi, Gi-Ae Kim, Seungbong Han, Young-Suk Lim
American Journal of Gastroenterology.2020; 115(3): 406. CrossRef
Approach to the patient with chronic hepatitis B and decompensated cirrhosis
Mitchell L. Shiffman
Liver International.2020; 40(S1): 22. CrossRef
Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up
Chong Teik Lim, George Boon Bee Goh, Huihua Li, Tony Kiat-Hon Lim, Wei Qiang Leow, Wei Keat Wan, Rafay Azhar, Wan Cheng Chow, Rajneesh Kumar
Microbiology Insights.2020;[Epub] CrossRef
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B
Han Ah Lee, Yeon Seok Seo, Seung Up Kim
Gastroenterology.2020; 158(8): 2310. CrossRef
Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B
Hyeki Cho, Young Chang, Jeong-Hoon Lee, Young Youn Cho, Joon Yeul Nam, Yun Bin Lee, Dong Ho Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jeong Min Lee, Jung-Hwan Yoon
Journal of Clinical Gastroenterology.2020; 54(7): 633. CrossRef
A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
Hira Hanif, Muzammil M. Khan, Mukarram J. Ali, Pir A. Shah, Jinendra Satiya, Daryl T.Y. Lau, Aysha Aslam
Microorganisms.2020; 8(10): 1526. CrossRef
Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune‐tolerant phase—authors' reply
Han Ah Lee, Seung Up Kim
Alimentary Pharmacology & Therapeutics.2020; 52(6): 1094. CrossRef
The Effects of Hepatic Steatosis on the Natural History of HBV Infection
Idrees Suliman, Noha Abdelgelil, Farah Kassamali, Tarek I. Hassanein
Clinics in Liver Disease.2019; 23(3): 433. CrossRef

13,015 View
377 Download
91 Web of Science
Crossref

Viral hepatitis

Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study: Dae Won Jun, Byung Ik Kim, Yong Kyun Cho, Hong Ju Kim, Young Oh Kwon, Soo Young Park, Sang Young Han, Yang Hyun Baek, Yong Jin Jung, Hwi Young Kim, Won Kim, Jeong Heo, Hyun Young Woo, Seong Gyu Hwang, Kyu Sung Rim, Jong Young Choi, Si Hyun Bae, Young Sang Lee, Young Suck Lim, Jae Youn Cheong, Sung Won Cho, Byung Seok Lee, Seok Hyun Kim, Joo Hyun Sohn, Tae Yeob Kim, Yong Han Paik, Ja Kyung Kim, Kwan Sik Lee; Clin Mol Hepatol 2013;19(2):165-172.
Published online June 27, 2013; DOI: https://doi.org/10.3350/cmh.2013.19.2.165

Abstract
PDF

Background/Aims

Carnitine and vitamin complex (Godex®) is widely used in patients with chronic liver disease who show elevated liver enzyme in South Korea. The purpose of this study is to identify the efficacy and safety of carnitine from entecavir combination therapy in Alanine aminotransferase (ALT) elevated Chronic Hepatitis B (CHB) patients.

Methods

130 treatment-naïve patients with CHB were enrolled from 13 sites. The patients were randomly selected to the entecavir and the complex of entecavir and carnitine. The primary endpoint of the study is ALT normalization level after 12 months.

Results

Among the 130 patients, 119 patients completed the study treatment. The ALT normalization at 3 months was 58.9% for the monotherapy and 95.2% for the combination therapy (P<0.0001). ALT normalization rate at 12 months was 85.7% for the monotherapy and 100% for the combination group (P=0.0019). The rate of less than HBV DNA 300 copies/mL at 12 months was not statistically significant (P=0.5318) 75.9% for the monotherapy, 70.7% for the combination and it was. Quantification of HBsAg level was not different from the monotherapy to combination at 12 months. Changes of ELISPOT value to evaluate the INF-γ secretion by HBsAg showed the increasing trend of combination therapy compare to mono-treatment.

Conclusions

ALT normalization rate was higher in carnitine complex combination group than entecavir group in CHB. Combination group was faster than entecavir mono-treatment group on ALT normalization rate. HBV DNA normalization rate and the serum HBV-DNA level were not changed by carnitine complex treatment.

Citations

Citations to this article as recorded by

Developments in small molecule antiviral drugs against hepatitis B and C viruses: FDA approved therapies and new drugs in clinical trials
Palak K. Parikh, Nisha H. Parikh, Mahalakshmi B, Ketan M. Ranch, Sai H.S. Boddu, Jayachandra Babu R, Amit K. Tiwari
Arabian Journal of Chemistry.2023; 16(8): 105013. CrossRef
Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients
Hyung Joon Yim, Won Kim, Sang Hoon Ahn, Young Kul Jung, Soon Ho Um, Joo Hyun Sohn, Jae Young Jang, Dong Joon Kim, Eun‐Sook Park, So‐Young Jin, Kyun‐Hwan Kim
Journal of Gastroenterology and Hepatology.2022; 37(2): 378. CrossRef
Hepatocyte-Derived L-Carnitine Restricts Hepatitis B Surface Antigen Loss Through an Immunosuppressive Effect on Germinal Center–Related Immune Cells
Shuqin Gu, Weibin Wang, Guofu Ye, Chengcong Chen, Yang Zhou, Ling Guo, Shihong Zhong, Xiaoyi Li, Xin Fu, Chunhua Wen, Libo Tang, Jian Sun, Jinlin Hou, Yongyin Li
The Journal of Infectious Diseases.2022; 225(11): 1955. CrossRef
Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, double-blind, placebo-controlled study
Eileen L. Yoon, Sang Bong Ahn, Dae Won Jun, Yong Kyun Cho, Do Seon Song, Jae Yoon Jeong, Hee Yeon Kim, Young Kul Jung, Myeong Jun Song, Sung Eun Kim, Hyoung Su Kim, Soung Won Jeong, Sang Gyune Kim, Tae Hee Lee
The Korean Journal of Internal Medicine.2022; 37(4): 757. CrossRef
Impact of l-Carnitine Supplementation on Liver Enzyme Normalization in Patients with Chronic Liver Disease: A Meta-Analysis of Randomized Trials
Hyunwoo Oh, Chan Hyuk Park, Dae Won Jun
Journal of Personalized Medicine.2022; 12(7): 1053. CrossRef
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
Clinical and Molecular Hepatology.2022; 28(3): 425. CrossRef
Prolonged Use of Carnitine-Orotate Complex (Godex®) Is Associated with Improved Mortality: A Nationwide Cohort Study
Kye-Yeung Park, Sangmo Hong, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park
Journal of Personalized Medicine.2022; 12(12): 1970. CrossRef
Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update
Na Li, Hui Zhao
Frontiers in Medicine.2021;[Epub] CrossRef
High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection
Shuqin Gu, Xin Fu, Guofu Ye, Chengcong Chen, Xiaoyi Li, Shihong Zhong, Libo Tang, Haitao Chen, Deke Jiang, Jinlin Hou, Yongyin Li
Frontiers in Immunology.2021;[Epub] CrossRef
Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B
Jeong Eun Song, Jun Yong Park
Expert Opinion on Pharmacotherapy.2021; 22(18): 2427. CrossRef
Carnitine Orotate Complex Ameliorates Insulin Resistance and Hepatic Steatosis Through Carnitine Acetyltransferase Pathway
Jung-Hee Hong, Moon-Kyu Lee
Diabetes & Metabolism Journal.2021; 45(6): 933. CrossRef
Does l-carnitine supplementation affect serum levels of enzymes mainly produced by liver? A systematic review and meta-analysis of randomized controlled clinical trials
Farzaneh Pirmadah, Nahid Ramezani-Jolfaie, Mohammad Mohammadi, Nasir Talenezhad, Cain C. T. Clark, Amin Salehi-Abargouei
European Journal of Nutrition.2020; 59(5): 1767. CrossRef
The protective role of l-carnitine against 1st- and 2nd-generation antihistamine-induced liver injury in mice
Rania A. Abdel-Emam, Esraa A. Ahmed, Marwa F. Ali
Comparative Clinical Pathology.2020; 29(1): 213. CrossRef
Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B
Yeon Woo Jung, Moonhyun Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
Journal of Korean Medical Science.2020;[Epub] CrossRef
Effects of carnitine supplementation on liver aminotransferase enzymes: A systematic review and meta-analysis of randomized controlled clinical trials
Esmaeil Yousefi Rad, Elham Eslampour, Ebrahim Falahi, Mahnaz Mardani, Azita Hekmatdoost, Omid Asbaghi, Somayeh Saboori
Indian Journal of Gastroenterology.2019; 38(6): 470. CrossRef
L‐Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis
Masatsugu Ohara, Koji Ogawa, Goki Suda, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Kazuharu Suzuki, Akihisa Nakamura, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Shunsuke Ohnishi,
Hepatology Communications.2018; 2(8): 910. CrossRef
Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature
Rachael R. Schulte, Manasi V. Madiwale, Allyson Flower, Jessica Hochberg, Michael J. Burke, Jennifer L. McNeer, Adam DuVall, Archie Bleyer
Leukemia & Lymphoma.2018; 59(10): 2360. CrossRef
Anti-adipogenic and antiviral effects ofl-carnitine on hepatitis C virus infection
Yoko Tsukuda, Goki Suda, Seiji Tsunematsu, Jun Ito, Fumiyuki Sato, Katsumi Terashita, Masato Nakai, Takuya Sho, Osamu Maehara, Tomoe Shimazaki, Megumi Kimura, Kenichi Morikawa, Mitsuteru Natsuizaka, Koji Ogawa, Shunsuke Ohnishi, Makoto Chuma, Naoya Sakamo
Journal of Medical Virology.2017; 89(5): 857. CrossRef
Glycyrrhetic acid, but not glycyrrhizic acid, strengthened entecavir activity by promoting its subcellular distribution in the liver via efflux inhibition
Qianying Chen, Hongzhu Chen, Wenjie Wang, Jiali Liu, Wenyue Liu, Ping Ni, Guowei Sang, Guangji Wang, Fang Zhou, Jingwei Zhang
European Journal of Pharmaceutical Sciences.2017; 106: 313. CrossRef
A Case of Therapeutic Laser for Suggested Drug Induced Liver Injury Patient during Treatment of Korean Medicine
Kyeong-Tae Lim, Byung-Cheul Shin, Eui-Hyoung Hwang, In Heo, Byung-Jun Kim, Kwang-Ho Heo
Journal of Korean Medicine Rehabilitation.2016; 26(3): 183. CrossRef
Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition
Zhongqi Dong, Sean Ekins, James E. Polli
European Journal of Pharmaceutical Sciences.2015; 66: 1. CrossRef
Comparison on the Efficacy and Safety of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycholic Acid in Patients with Abnormal Alanine Aminotransferase: Multicenter, Double-blinded, Randomized, Active-controlled Clinical Trial
Sae Hwan Lee, Gab Jin Cheon, Hong Soo Kim, Young Don Kim, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kim
The Korean Journal of Gastroenterology.2014; 64(1): 31. CrossRef